Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,122 public posts
Filter results
Abiraterone Active in Androgen Receptor-Positive Salivary Tumors — Disease control in 62.5% of a small cohort . . . MedPage Today - 10/14/21
xid=nl_mpt_DHE_2021-10-15 and also to the ASCO full report out of Italy:
Abiraterone Acetate in Patients With
-Resistant, Androgen Receptor–Expressing Salivary Gland Cancer: A Phase II Trial https://ascopubs.org/doi/full/10.1200/JCO.21.00468 [i] Knowledge is power, so stay Informed
xid=nl_mpt_DHE_2021-10-15 and also to the ASCO full report out of Italy:
Abiraterone Acetate in Patients With
-Resistant, Androgen Receptor–Expressing Salivary Gland Cancer: A Phase II Trial https://ascopubs.org/doi/full/10.1200/JCO.21.00468 [i] Knowledge is power, so stay Informed
cujoe
in
Fight Prostate Cancer
3 years ago
Glutaminase inhibitor trial
There were some posts recently re the possible role of the glutaminase switch in leading to
castration
resistance.
There were some posts recently re the possible role of the glutaminase switch in leading to
castration
resistance.
hg115pb
in
Advanced Prostate Cancer
3 years ago
Androgen Receptor Signalling Inhibitors – Post-Chemotherapy, Pre-Chemotherapy and now in castration sensitive prostate cancer - ERC -6.15.21
Androgen Receptor Signalling Inhibitors – Post-Chemotherapy, Pre-Chemotherapy and now in
sensitive prostate cancer - Nicholas Mitsiades and Salma Kaochar, Dept. of Medicine and Dept. of Molecular and Cellular Biology, Baylor College of Medicine, Houston,TX 77030.
Androgen Receptor Signalling Inhibitors – Post-Chemotherapy, Pre-Chemotherapy and now in
sensitive prostate cancer - Nicholas Mitsiades and Salma Kaochar, Dept. of Medicine and Dept. of Molecular and Cellular Biology, Baylor College of Medicine, Houston,TX 77030.
cujoe
in
Fight Prostate Cancer
3 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel - MDA/UBA, 01.15.2021
In summary, our studies reveal the key metabolites fueling
castration
resistant progression in the context of a partial or complete loss of AR dependence.
In summary, our studies reveal the key metabolites fueling
castration
resistant progression in the context of a partial or complete loss of AR dependence.
cujoe
in
Fight Prostate Cancer
3 years ago
Testosterone Cycling (BAT) provides enhancement of body composition and QOL
Perhaps not so surprising after all. https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.15408
Reversing the effects of androgen-deprivation therapy in men with metastatic
-resistant prostate cancer Catherine H.
Perhaps not so surprising after all. https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.15408
Reversing the effects of androgen-deprivation therapy in men with metastatic
-resistant prostate cancer Catherine H.
MateoBeach
in
Advanced Prostate Cancer
3 years ago
No intensification - is doc too laid back?
Is there any reasonable chance of delaying time to
castration
resistance and new mets by doing this? Can such treatments hit undetected micrometastasis around the single confirmed and zapped met or in other parts of my bones?
Is there any reasonable chance of delaying time to
castration
resistance and new mets by doing this? Can such treatments hit undetected micrometastasis around the single confirmed and zapped met or in other parts of my bones?
Purple-Bike
in
Advanced Prostate Cancer
3 years ago
Statins and adrenal androgen levels in prostate cancer: A new twist
However, a potential impact of statins on de novo intratumoural steroid synthesis is unlikely in primary prostate tumours or in a substantial subset of
castration
resistant PCa (CRPC) tumours, in which the key enzymes required for de novo androgen synthesis (e.g.
However, a potential impact of statins on de novo intratumoural steroid synthesis is unlikely in primary prostate tumours or in a substantial subset of
castration
resistant PCa (CRPC) tumours, in which the key enzymes required for de novo androgen synthesis (e.g.
pjoshea13
in
Advanced Prostate Cancer
3 years ago
The Metabolic Syndrome [MetS] & PCa
." *** {This post was prompted by the recent post from noahware: his title - "
Statins: new study regarding time to CRPC
" study title - "
Metabolic syndrome and its pharmacologic treatment are associated with the time to
-resistant prostate cancer" "[u][i]Importantly, in men with
." *** {This post was prompted by the recent post from noahware: his title - "
Statins: new study regarding time to CRPC
" study title - "
Metabolic syndrome and its pharmacologic treatment are associated with the time to
-resistant prostate cancer" "[u][i]Importantly, in men with
pjoshea13
in
Advanced Prostate Cancer
2 years ago
Androgen receptor (AR) heterogeneity ... and therapy resistance
Hormone therapy in the form of medical or surgical
castration
remains the mainstay of systemic treatment in prostate cancer.
Hormone therapy in the form of medical or surgical
castration
remains the mainstay of systemic treatment in prostate cancer.
pjoshea13
in
Advanced Prostate Cancer
3 years ago
Bipolar Androgen Therapy (BAT) update (with olaparib)
repair defects • 3 of 6 90+% progressors had DNA damage repair defects • 5 patients had serious (grade ≥ 3) toxicity, including one death https://www.urotoday.com/conference-highlights/esmo-2021/esmo-2021-prostate-cancer/132121-esmo-2021-bipolar-androgen-therapy-bat-plus-olaparib-in-men-with-metastatic-
castration
-resistant-prostate-cancer.html
repair defects • 3 of 6 90+% progressors had DNA damage repair defects • 5 patients had serious (grade ≥ 3) toxicity, including one death https://www.urotoday.com/conference-highlights/esmo-2021/esmo-2021-prostate-cancer/132121-esmo-2021-bipolar-androgen-therapy-bat-plus-olaparib-in-men-with-metastatic-
castration
-resistant-prostate-cancer.html
Tall_Allen
in
Advanced Prostate Cancer
3 years ago
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, CRPC
"The majority of patients with metastatic
castration
-resistant prostate cancer (mCRPC) will have disease progression of a uniformly fatal disease. mCRPC is driven by both activated androgen receptors and elevated intratumoural androgens; however, the current standard of care is therapy that targets a
"The majority of patients with metastatic
castration
-resistant prostate cancer (mCRPC) will have disease progression of a uniformly fatal disease. mCRPC is driven by both activated androgen receptors and elevated intratumoural androgens; however, the current standard of care is therapy that targets a
pjoshea13
in
Advanced Prostate Cancer
3 years ago
prednisone etc
My hot flashes are somewhat under control but the other symptoms of
castration
seem to be getting worse. Today I had such muscle weakness that i had a hard time walking. Muscles did not cooperate. I hope this i just from the lack of prednisone. Is retaining fluid in feet normal?
My hot flashes are somewhat under control but the other symptoms of
castration
seem to be getting worse. Today I had such muscle weakness that i had a hard time walking. Muscles did not cooperate. I hope this i just from the lack of prednisone. Is retaining fluid in feet normal?
spencoid2
in
Advanced Prostate Cancer
3 years ago
The Vision Trial - Offering Real Hope for the Heavily Treated MCRPC Patient
Key findings showed a significant improvement in overall survival with the addition of targeted radioligand therapy LuPSMA) to the standard of care in patients with progressive PSMA positive metastatic
castration
resistant cancer.
Key findings showed a significant improvement in overall survival with the addition of targeted radioligand therapy LuPSMA) to the standard of care in patients with progressive PSMA positive metastatic
castration
resistant cancer.
marnieg46
in
Fight Prostate Cancer
3 years ago
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Androgen receptor (AR) antagonists play a pivotal role in the treatment of metastatic
castration
-resistant prostate cancer (mCRPC), but they still face the problem of drug resistance.
Androgen receptor (AR) antagonists play a pivotal role in the treatment of metastatic
castration
-resistant prostate cancer (mCRPC), but they still face the problem of drug resistance.
Scout4answers
in
Advanced Prostate Cancer
2 years ago
obesity paradox?—improved survival outcomes in mCRPC patients with a high body mass index (BMI)
Wagaskar, MBBS, highlights a study presented at the 2021 European Association of Urology Congress which reported evidence of the obesity paradox in patients with metastatic
castration
-resistant prostate cancer (mCRPC). https://www.urologytimes.com/view/dr-wagaskar-explains-the-obesity-paradox-in-prostate-cancer
Wagaskar, MBBS, highlights a study presented at the 2021 European Association of Urology Congress which reported evidence of the obesity paradox in patients with metastatic
castration
-resistant prostate cancer (mCRPC). https://www.urologytimes.com/view/dr-wagaskar-explains-the-obesity-paradox-in-prostate-cancer
JRPnSD
in
Advanced Prostate Cancer
3 years ago
BAT, SAT & SARMs
SAT may counter adaptive cellular mechanisms that contribute to a
castration
-resistant phenotype.
SAT may counter adaptive cellular mechanisms that contribute to a
castration
-resistant phenotype.
pjoshea13
in
Advanced Prostate Cancer
3 years ago
Darolutamide vs. Apalutamide vs. Enzalutamide
Consideration of these adverse events is important in clinical decision-making and treatment selection in nonmetastatic
castration
-resistant prostate cancer.
Consideration of these adverse events is important in clinical decision-making and treatment selection in nonmetastatic
castration
-resistant prostate cancer.
MateoBeach
in
Advanced Prostate Cancer
3 years ago
Docetaxel or Abiraterone in Metastatic Castration-Sensitive Prostate Cancer [mCSPC]
PMID: 34026638 PMCID: PMC8138065 DOI: 10.3389/fonc.2021.658331 Abstract Background: Both Docetaxel (DOC) and Abiraterone (ABI) improve the survival of men with metastatic,
castration
sensitive prostate cancer (mCSPC).
PMID: 34026638 PMCID: PMC8138065 DOI: 10.3389/fonc.2021.658331 Abstract Background: Both Docetaxel (DOC) and Abiraterone (ABI) improve the survival of men with metastatic,
castration
sensitive prostate cancer (mCSPC).
pjoshea13
in
Advanced Prostate Cancer
3 years ago
Metformin Possibly Beneficial in Advanced Prostate Cancer
https://www.endocrinologyadvisor.com/home/topics/diabetes/metformin-added-to-adt-delays-development-of-
castration
-resistant-prostate-cancer/ https://www.sciencedirect.com/science/article/abs/pii/S1078143921002283?dgcid=raven_sd_aip_email
https://www.endocrinologyadvisor.com/home/topics/diabetes/metformin-added-to-adt-delays-development-of-
castration
-resistant-prostate-cancer/ https://www.sciencedirect.com/science/article/abs/pii/S1078143921002283?dgcid=raven_sd_aip_email
dorke
in
Advanced Prostate Cancer
3 years ago
PCa-specific Survival after Radical Prostatectomy Is Improved by Metformin but not other Antidiabetic Drugs
Poorly controlled diabetes increases the risk of metastases and
castration
-resistant prostate cancer in men undergoing radical prostatectomy: results from the SEARCH database. Cancer. 2019;125:2861–2867. - PMC - PubMed Murtola T.J., Sälli S.M., Talala K., Taari K., Tammela T.J., Auvinen A.
Poorly controlled diabetes increases the risk of metastases and
castration
-resistant prostate cancer in men undergoing radical prostatectomy: results from the SEARCH database. Cancer. 2019;125:2861–2867. - PMC - PubMed Murtola T.J., Sälli S.M., Talala K., Taari K., Tammela T.J., Auvinen A.
pjoshea13
in
Advanced Prostate Cancer
2 years ago
1
...
19
20
21
...
57
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
999 results
Fight Prostate Cancer
67 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest